A patient already on salbutamol and ipratropium continues to have nocturnal exacerbations of asthma. What is the next step?

Explanation

## Correct Answer: C. LABA plus inhalation steroids The patient is already on a short-acting beta-2 agonist (salbutamol) and an anticholinergic (ipratropium), yet experiencing nocturnal exacerbations—a hallmark of **inadequately controlled asthma**. According to GINA guidelines and Indian asthma management protocols, nocturnal symptoms indicate the need to step up therapy. The patient has not yet received **inhaled corticosteroids (ICS)**, which are the cornerstone of asthma control therapy. The addition of a **long-acting beta-2 agonist (LABA) plus ICS** addresses two critical gaps: (1) ICS provides anti-inflammatory control to prevent exacerbations, and (2) LABA provides sustained bronchodilation over 12 hours, preventing nocturnal symptoms. This combination (ICS-LABA) is the standard step-up from SABA monotherapy in Indian guidelines (RNTCP/NTEP asthma management) and represents the evidence-based next step. The presence of nocturnal exacerbations specifically indicates loss of control and mandates controller therapy, not just reliever therapy. ## Why the other options are wrong **A. Oral corticosteroids** — Oral corticosteroids are reserved for acute exacerbations or severe uncontrolled asthma requiring hospitalization, not for step-up maintenance therapy. They carry significant systemic side effects (hyperglycemia, osteoporosis, immunosuppression) and are not first-line for nocturnal exacerbations in stable patients. ICS inhalation is far superior for chronic control. **B. Increase the dose of salbutamol** — Increasing SABA dose addresses only acute symptom relief, not the underlying inflammation driving nocturnal exacerbations. Escalating SABA without adding controller therapy (ICS) is ineffective and may mask worsening control. SABA monotherapy cannot prevent exacerbations; anti-inflammatory therapy is essential. **D. Montelukast** — Montelukast (a leukotriene receptor antagonist) is an add-on controller but is **less effective than ICS-LABA** for nocturnal asthma control. It may be considered as an alternative in aspirin-sensitive asthma or exercise-induced asthma, but ICS-LABA is the preferred step-up. Montelukast alone does not address the inflammatory basis of nocturnal exacerbations adequately. ## High-Yield Facts - **Nocturnal asthma exacerbations** indicate loss of control and mandate step-up to controller therapy (ICS), not just reliever escalation. - **ICS-LABA combination** is the standard step-up from SABA monotherapy in GINA and Indian asthma guidelines for inadequately controlled asthma. - **LABA provides 12-hour bronchodilation**, preventing nocturnal symptoms; ICS provides anti-inflammatory control to reduce exacerbation frequency. - **Ipratropium** (anticholinergic) is a reliever, not a controller; it does not prevent exacerbations and cannot substitute for ICS. - **Oral corticosteroids** are for acute exacerbations or severe persistent asthma, not routine step-up maintenance therapy due to systemic toxicity. ## Mnemonics **STEP-UP Asthma Control (GINA/Indian Guidelines)** **S**ABA alone → **T**hink ICS needed → **E**scalate to **P**owerful combo (ICS-LABA) → **U**se for **P**ersistent symptoms (nocturnal = persistent). Nocturnal exacerbations = skip SABA escalation, go straight to ICS-LABA. **Nocturnal Asthma = Controller Deficiency** Night symptoms = **No** controller (ICS). Add **ICS-LABA**, not more SABA. Remember: SABA is a reliever (rescue), ICS-LABA is a controller (prevention). ## NBE Trap NBE may lure students into escalating SABA dose (option B) by framing the question as "continuing exacerbations despite current therapy," making students think "increase what's already working." The trap is confusing **reliever escalation** with **controller therapy**—nocturnal symptoms demand anti-inflammatory control (ICS), not more bronchodilator. ## Clinical Pearl In Indian primary care, nocturnal asthma is often mistaken for cardiac dyspnea or GERD. The key discriminator is that nocturnal asthma responds to ICS-LABA, not to increased SABA or antacids. A patient waking at night with wheeze and dyspnea, already on SABA + anticholinergic, needs ICS-LABA to prevent recurrent nighttime exacerbations and improve quality of life. _Reference: GINA Guidelines 2023; Harrison Ch. 253 (Asthma); KD Tripathi Ch. 27 (Bronchodilators & Asthma Management); Indian Asthma Management Guidelines (RNTCP/NTEP)_